Finoriq research workspace
Compass Therapeutics, Inc. (CMPX) Institutional Holdings & 13F Ownership
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company. Review CMPX institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- Company
- Compass Therapeutics, Inc. (CMPX)
- Ticker
- CMPX
- Market Cap
- $366.5M
- Latest Price
- $2.035
- Industry
- Biotech & Pharma
Compass Therapeutics, Inc. (CMPX) Top Institutional Holders
Top current 13F holders indexed for Compass Therapeutics, Inc. (CMPX). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Ken FisherCIK 0000850529 | $7.1M | 0.0% | Filing2026-05-05 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.